12:33 PM
 | 
Dec 22, 2017
 |  BC Extra  |  Company News

Agile gets second CRL for Twirla

Agile Therapeutics Inc. (NASDAQ:AGRX) was off $2.24 (47%) to $2.52 on Friday after FDA issued a second complete response letter for Twirla (AG200-15), its...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >